All In Biotech

Drug Trial Radar · NCT04989803

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

247

Planned (sponsor's estimate)

Start

Oct 27, 2021

Primary completion

Feb 2030

Study completion Feb 2030

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

Conditions

  • Relapsed and/or Refractory B-cell Lymphoma

Interventions

  • CyclophosphamideDrug

    Lymphodepleting chemotherapy administered intravenously

  • FludarabineDrug

    Lymphodepleting chemotherapy administered intravenously

  • KITE-363Biological

    A single infusion of CAR-transduced autologous T cells administered intravenously

  • KITE-753Biological

    A single infusion of CAR-transduced autologous T cells administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753Time frame: Up to 28 days
  2. Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.Time frame: Up to 24 months
  3. Phase 2: ORR as per central assessment for KITE-753Time frame: Up to 36 months

Locations

36 sites in 6 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • Stanford Cancer Institute

    Stanford, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northside Hospital

    Atlanta, Georgia

  • University of Illinois Chicago

    Chicago, Illinois

  • Midwestern Regional Medical Center, Inc.City of Hope Chicago

    Park Ridge, Illinois

  • Norton Cancer Institute, St. Matthews Campus

    Shelbyville, Kentucky

  • University of MD, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University Irving Medical Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • The Ohio State University Wexner Medical Center - James Cancer Hospital

    Columbus, Ohio

  • Tennessee Oncology, PLLC - Investigational Drug Services

    Nashville, Tennessee

  • Vanderbilt University

    Nashville, Tennessee

  • St. David's Medical Center

    Austin, Texas

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Swedish Cancer Institute

    Seattle, Washington

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Concord Repatriation General Hospital

    Sydney, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Monash Health, Monash Medical Centre

    Clayton, Victoria, Australia

  • Epworth Healthcare

    East Melbourne, Victoria, Australia

  • St. Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Cross Cancer Center

    Edmonton, Canada

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Canada

  • Jewish General Hospital

    Montreal, Canada

  • McGill University Health Center

    Montreal, Canada

  • Princess Margaret Cancer Centre - University Health Network

    Toronto, Canada

  • Universitatsklinikum Wurzburg

    Würzburg, Germany

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • King's College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.